Opinion
Video
Bispecifics for Third Line Therapy of R/R DLBCL
Author(s):
Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.
EP: 1.Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma
EP: 2.Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL
EP: 3.Treatment Selection in Second Line R/R DLBCL
EP: 4.Tafasitamab and Lenalidomide for R/R DLBCL
EP: 5.Real-World Outcomes of Tafasitamab-Lenalidomide for Patients with R/R DLBCL
EP: 6.The Role of CAR T-Cell Therapy in R/R DLBCL
EP: 7.Data Updates: CAR T in the ZUMA-7 and TRANSFORM Trials for R/R DLBCL
EP: 8.Clinical Perspectives of CAR T in R/R Diffuse Large B-Cell Lymphoma
EP: 9.Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL
EP: 10.Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting
Now Viewing
EP: 11.Bispecifics for Third Line Therapy of R/R DLBCL
EP: 12.R/R DLBCL: Safety Considerations for Bispecific Antibodies
EP: 13.Treatment Sequencing of Later Line Therapies in R/R DLBCL
EP: 14.Additional Data Updates from ASH 2023
EP: 15.Future Outlooks in the Treatment of R/R DLBCL
Related Videos
Related Content
